Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

714

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab 200 mg
RADIATION: Radiotherapy 60 Gray
RADIATION: Radiotherapy 66 Gray
RADIATION: Radiotherapy 70 Gray
DRUG: Cisplatin 100 mg/m^2

Sponsor

Merck Sharp & Dohme LLC